Kerendia

(Finerenone)

Kerendia

Drug updated on 11/15/2023

Dosage FormTablets (oral; 10 mg, 20 mg)
Drug ClassNon-steroidal mineralocorticoid receptor antagonists
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated to reduce the risk of sustained eGFR decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).

Product Monograph / Prescribing Information

Document TitleYearSource
Kerendia (finerenone) Prescribing Information.2022Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Clinical and pharmacoeconomic combined report.2023CADTH
Finerenone in type 2 diabetes and renal outcomes: A random-effects model meta-analysis.2023Frontiers in Endocrinology
Efficacy and safety of finerenone for prevention of cardiovascular events in type 2 diabetes mellitus with chronic kidney disease: a meta-analysis of randomized controlled trials.2023Journal of Cardiovascular Pharmacology
Efficacy and safety of finerenone in chronic kidney disease and type 2 diabetes patients: a systematic review and meta-analysis.2023Annals of Medicine & Surgery
A systematic review and meta-analysis on the efficacy and safety of finerenone therapy in patients with cardiovascular and chronic kidney diseases in type 2 diabetes mellitus.2023Cureus
Australian public assessment report for finerenone. 2022Australian Government: Department of Health
Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes: a systematic review incorporating an indirect comparisons meta-analysis.2022Frontiers in Pharmacology
Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease.2022Frontiers in Pharmacology
Finerenone in diabetic kidney disease: a systematic review and critical appraisal.2022Diabetes & Metabolic Syndrome
Efficacy and safety of finerenone in chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials.2022Frontiers in Pharmacology
Meta-analysis of the efficacy and safety of finerenone in diabetic kidney disease.2022Kidney and Blood Pressure Research
Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes: a systematic review incorporating an indirect comparisons meta-analysis.2022Frontiers in Pharmacology
Efficacy and safety of finerenone in chronic kidney disease associated with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials.2022European Journal of Clinical Pharmacology
Effect of finerenone on cardiovascular events in kidney disease and/or diabetes: a meta analysis of randomized control trials.2022International Urology and Nephrology
Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease.2022Cardiovascular Diabetology
Efficacy and safety of finerenone in patients with chronic kidney disease: a systematic review with meta-analysis and trial sequential analysis.2021Annals of Palliative Medicine
Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials.2019Heart Failure Reviews
The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure.2018Medicine

Clinical Practice Guidelines